Biosimulation Market Worth $10.0 Billion By 2030 | CAGR: 16.9%

Biosimulation Market Growth & Trends

The global biosimulation market size is expected to reach USD 10.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2023 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

 Request a free sample copy or view the report summary: Biosimulation Market Report

Biosimulation Market Report Highlights

• By product, software dominated the market in 2022. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification

• The drug development application segment accounted for the largest revenue share of more than 59.7% in 2022

• By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2022 due to the increasing strategic initiatives

• North America grabbed the largest revenue share of over 49.6% in 2022. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period

• The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

Biosimulation Market Segmentation

Grand View Research has segmented the global biosimulation market based on product, application, end-use, and region:

Biosimulation Product Outlook (Revenue, USD Million, 2017 - 2030)

• Software

• Services

  • In-house Services

  • Contract Services

Biosimulation Application Outlook (Revenue, USD Million, 2017 - 2030)

• Drug Development

• Drug Discovery

• Others

Biosimulation  By Delivery Model (Revenue, USD Million, 2017 - 2030)

• Subscription Models

• Ownership Models

Biosimulation End-use Outlook (Revenue, USD Million, 2017 - 2030)

• Pharmaceutical & Biotechnology Companies

• CROs

• Regulatory Authorities

• Academic Research Institutions

Biosimulation Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Mexico

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait 

List of Key Players of the Biosimulation Market

• Certara, USA

• Dassault Systemes

• Advanced Chemistry Development

• Simulation Plus

• Schrodinger, Inc.

• Chemical Computing Group ULC

• Physiomics Plc

• Rosa & Co. LLC

• BioSimulation Consulting Inc.

• Genedata AG

• Instem Group of Companies

• PPD, Inc.

• Yokogawa Insilico Biotechnology GmbH

• Immunetrics